Steward Partners Investment Advisory LLC Grows Stake in Becton, Dickinson and Company $BDX

Key Points

• Steward Partners Investment Advisory LLC increased its stake in Becton, Dickinson and Company by 4.8%, holding 29,485 shares valued at approximately $6.75 million.
• In its latest earnings report, Becton, Dickinson exceeded expectations with an earnings per share (EPS) of $3.68 and reported revenue of $5.51 billion, marking a 10.4% increase from the previous year.
• The company recently declared a quarterly dividend of $1.04 per share with an annualized yield of 2.1%, payable on September 30th to shareholders on record as of September 8th.

Steward Partners Investment Advisory LLC raised its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 4.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,485 shares of the medical instruments supplier's stock after purchasing an additional 1,343 shares during the period. Steward Partners Investment Advisory LLC's holdings in Becton, Dickinson and Company were worth $6,754,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Brighton Jones LLC raised its position in Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after purchasing an additional 877 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its position in Becton, Dickinson and Company by 50.6% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier's stock valued at $18,808,000 after purchasing an additional 27,581 shares during the last quarter. Foster Victor Wealth Advisors LLC bought a new position in Becton, Dickinson and Company during the 1st quarter valued at approximately $6,406,000. GAMMA Investing LLC raised its position in Becton, Dickinson and Company by 29.9% during the 1st quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier's stock valued at $744,000 after purchasing an additional 748 shares during the last quarter. Finally, Ritholtz Wealth Management bought a new position in Becton, Dickinson and Company during the 1st quarter valued at approximately $224,000. Institutional investors own 86.97% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on BDX shares. Morgan Stanley increased their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Citigroup lowered Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and decreased their target price for the stock from $217.00 to $185.00 in a research report on Thursday, May 22nd. Bank of America lowered Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 target price for the company. in a research report on Thursday, May 1st. Barclays decreased their target price on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research report on Tuesday, June 3rd. Finally, William Blair lowered Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research report on Thursday, May 1st. Four research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $211.44.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the sale, the executive vice president directly owned 4,575 shares in the company, valued at approximately $783,194.25. This trade represents a 20.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the sale, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 3,214 shares of company stock worth $579,206. Insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Stock Up 1.5%

Shares of Becton, Dickinson and Company stock traded up $2.8730 during midday trading on Friday, hitting $199.5030. The company had a trading volume of 1,619,788 shares, compared to its average volume of 2,720,196. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The stock has a market capitalization of $57.18 billion, a P/E ratio of 35.88, a P/E/G ratio of 1.49 and a beta of 0.20. The company has a 50 day moving average of $180.65 and a 200 day moving average of $195.26. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping the consensus estimate of $3.40 by $0.28. The company had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm's quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be paid a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 2.1%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 74.82%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.